Texas Southern University Receives $5.1M Grant for Cancer Research

CPRIT awarded Texas Southern University a $5.1 million Core Facility Support Award (RP180748) in August 2018 to fund a state-of-the-art drug development core facility. The core facility award also allowed Texas Southern University to continue to strengthen and expand its unique capabilities to serve cancer investigators from Texas and across the nation.

It is noteworthy that the National Cancer Institute (NCI) selected Texas Southern University as a designated laboratory to provide contract services for cancer drug discovery and development in the nation. NCI selected a total of 18 organizations for 2022–2027 cycle to participate NCI Experimental Therapeutics (NExT) program. Texas Southern University is the only institution in Texas and the only HBCU participating in the NExT program among a group of elite institutions such as Caltech, Vanderbilt, UCSF, and Georgetown.